$1.39
-0.03 (-2.11%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BDRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional · 1 expanded access
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaNCT05324501Safety of MTX110 administered by CEDNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic decision | Drug: MTX110 · Device: Programmable pump and catheter system | Recurrent Glioblastoma | 4 | 2024-09-10actual | 2025-02-10 |
| Expanded Access to 0.5 mg eRapa for Familial Adenomatous PolyposisNCT07689942expanded access | — | Available | Drug: eRapa (encapsulated rapamycin) | Familial Adenomatous Polyposis (FAP) | — | — | 2026-07-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19